IntraopeRativE Use of periNeal Block for Hemorrhoidectomy (IREN)
Intraoperative Use of Perineal Block for Hemorrhoidectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Hemorrhoidectomy, as has being demonstrated to be an effective method of treatment for stage III-IV hemorrhoidal disease. However it is associated with intense postoperative pain that requires the use of multimodal analgesia. Inadequate pain control leads to the prolongation of admission, increasing the consumption of opioid analgesics.
Traditionally spinal or general anesthesia is used in proctological practice. However, the number of studies about using of perianal local anesthesia, both in combination with general anesthesia and as a separate practice has been increasing recently.
Perineal block with the anesthesia of the pudendal nerve's terminal branches allows to perform a hemorrhoidectomy with the optimal intraoperative and postoperative analgesia. The drugs used for this have some pharmacological differences in the duration of the drug and the form of administration.
The aim of this prospective, randomized, double-blind study is to assess the effectiveness of the intraoperative use of perineal block with spinal anesthesia to reduce postoperative pain and the amount of used analgesics.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yuliia Churina
- Phone Number: +79154970361
- Email: churina@kkmx.ru
Study Contact Backup
- Name: Daniil Markaryan, PhD
- Phone Number: +79035329245
- Email: markaryan@kkmx.ru
Study Locations
-
-
-
Moscow, Russian Federation, 119435
- Recruiting
- Clinic of Colorectal and Minimally Invasive Surgery
-
Contact:
- Daniil Markaryan, PhD
- Phone Number: +79035329245
- Email: markaryan@kkmx.ru
-
Contact:
- Yuliia Churina, MD
- Phone Number: +79154970361
- Email: churina@kkmx.ru
-
Principal Investigator:
- Petr Tsarkov, Prof
-
Sub-Investigator:
- Bruno Roshe, Prof
-
Sub-Investigator:
- Daniil Markaryan, PhD
-
Sub-Investigator:
- Yuliia Churina, MD
-
Sub-Investigator:
- Yuliia Medkova, MD
-
Sub-Investigator:
- Inna Tulina, PhD
-
Sub-Investigator:
- Eduard Markaryan
-
Sub-Investigator:
- Mariana Dundua
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent.
- Patients over 18 years.
- Symptomatic grade III-IV hemorrhoids.
- Planned surgery: Milligan-Morgan hemorrhoidectomy.
Exclusion Criteria:
- Patient's refuse to participate in the study.
- Pregnancy.
- Сontraindications or technical inability to perform subarachnoid anesthesia.
- Decompensated somatic diseases.
- Inflammation of the perianal region.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: epinephrine + ropivacaine +saline
1% epinephrine solution + 30 ml of 1% ropivacaine solution diluted with 20 ml of 0.9% saline for achievement a 0.75% anesthetic solution in a ratio of 1: 200 000
|
Perineal block using solution of ropivocaine and epinephrine for the first group was performed.
Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus.
Ten ml of the solution is injected in ischiorectal fat on each side.
The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve.
In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial.
The total amount of the injected solution is 50 ml.
epinephrine + ropivacaine +saline
|
|
Placebo Comparator: epinephrine + saline
1% epinephrine solution + 50 ml of 0.9% saline in a ratio of 1: 200 000.
|
Perineal block using solution of ropivocaine and epinephrine for the first group was performed.
Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus.
Ten ml of the solution is injected in ischiorectal fat on each side.
The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve.
In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial.
The total amount of the injected solution is 50 ml.
epinephrine + saline
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The rate of opioid analgesics usage
Time Frame: 1 day - 2 weeks
|
The need to use opioid analgesics.
|
1 day - 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
systemic analgesics usage
Time Frame: 1 day - 2 weeks
|
The duration and frequency of systemic analgesics usage, including opioid and topical local anesthetics in early postoperative period.
The assessment of the required amount and frequency of NSAIDs (nonsteroidal anti-inflammatory drugs) usage in the first 24 hours, then - daily up to 7 days
|
1 day - 2 weeks
|
|
The duration of painless period after surgery
Time Frame: 1 day - 1 week
|
the time from the moment of the blockade to the need of intake the first dose of analgesics.
|
1 day - 1 week
|
|
re-admission
Time Frame: 1 day - 1 month
|
The need for re-admission after operation
|
1 day - 1 month
|
|
quality of life with SF-36 questionnaire
Time Frame: 1 day - 1 month
|
The assessment of quality of life after surgery using the SF-36 questionnaire (The Short Form-36).
Scale evaluates physical and mental status after operation.
|
1 day - 1 month
|
|
The timing of returning to work.
Time Frame: 1 day - 1 month
|
The period between surgery and returning to normal work
|
1 day - 1 month
|
|
early postoperative complications
Time Frame: 1 day - 1 month
|
Assessment of early postoperative complications (bleeding, retention of urine, infectious complications).
|
1 day - 1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Anesthetics, Local
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Ropivacaine
- Epinephrine
- Racepinephrine
- Epinephryl borate
Other Study ID Numbers
Other Study ID Numbers
- 1 (Mobile Health and Wellness Program)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.